With in-depth studies on the TGF-β pathway and SMAD proteins, SMAD proteins are expected to become important biomarkers for breast cancer diagnosis and provide therapeutic targets for breast cancer, especially for triple negative breast cancer with poor prognosis. Here, TGFB1 is linked to triple-negative breast carcinoma.